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With Angiotensin II Type 1 Receptor Antibodies
Meghan H. Pearl1, Jonathan Grotts2, Maura Rossetti3, Qiuheng Zhang3, David W. Gjertson3,
Patricia Weng1, David Elashoff2, Elaine F. Reed3 and Eileen Tsai Chambers4
1Department of Pediatrics, Division of Pediatric Nephrology, University of California, Los Angeles, Los Angeles, California,
USA; 2Department of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, California, USA; 3Depart-
ment of Pathology and Laboratory Medicine University of California, Los Angeles, Los Angeles, California, USA; and
4Department of Pediatrics, Division of Pediatric Nephrology, Duke University, Durham, North Carolina, USAIntroduction: Angiotensin II type 1 receptor antibody (AT1R-Ab), is a non–human leukocyte antigen (HLA)
antibody implicated in poor renal allograft outcomes, although its actions may be mediated through a
different pathway than HLA donor-specific antibodies (DSAs). Our aim was to examine serum cytokine
profiles associated with AT1R-Ab and distinguish them from those associated with HLA DSA in serially
collected blood samples from a cohort of pediatric renal transplant recipients.
Methods: Blood samples from 65 pediatric renal transplant recipients drawn during the first 3 months post-
transplant, at 6, 12, and 24months posttransplant, and during suspected episodes of kidney transplant rejection
were tested for AT1R-Ab, HLADSA, and a panel of 6 cytokines (tumor necrosis factor [TNF]-a, interferon [IFN]-g,
interleukin [IL]-8, IL-1b, IL-6, and IL-17). Associations between antibodies and cytokines were evaluated.
Results: AT1R-Ab, but not HLA DSA, was associated with elevations in TNF-a, IFN-g, IL-8, IL-1b, IL-6, and
IL-17. This relationship remained significant even after controlling for relevant clinical factors and was
consistent across all time points. In contrast to HLA DSA, AT1R-Ab was associated with elevations in
vascular inflammatory cytokines in the first 2 years posttransplant.
Conclusions: This profile of vascular cytokines may be informative for clinical monitoring and designing
future studies to delineate the distinct pathophysiology of AT1R-Ab–mediated allograft injury in kidney
transplantation.
Kidney Int Rep (2019) 4, 541–550; https://doi.org/10.1016/j.ekir.2018.12.011
KEYWORDS: angiotensin II type 1 receptor antibody; cytokine; human leukocyte antigen donor-specific antibody;
pediatric nephrology; transplantation
ª 2018 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A ntibody-mediated rejection (AMR) remains aleading cause of allograft failure and subsequently
contributes to the ongoing organ shortage in renal trans-
plantation.1–3 Both HLA DSAs and non-HLA autoanti-
bodies have been implicated in AMR, allograft
dysfunction, and failure.2,4–7 AT1R-Ab is a non-HLA anti-
body that has gained recognition for its detrimental effects
on the renal allograft, although its actions may be mediated
through a differentmechanistic pathway thanHLADSA.8,9
AT1R-Ab activates the AT1R, a G-protein–coupled
receptor located on endothelial and vascular smooth
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International Reports (2019) 4, 541–550muscle cells, which mediates the vasoconstrictive and
salt retention actions of angiotensin II.7 In addition to
these classical effects, activation of the AT1R also
triggers inflammatory and profibrotic pathways.10,11
HLA DSA alloantibodies bind to Class I and II HLA
receptors on the allograft endothelium. This interaction
stimulates endothelial cell activation, proliferation, and
migration, leading to the histological changes associ-
ated with acute and chronic AMR.12–15 Both AT1R-Ab
and HLA DSA can directly injure endothelial cells, and
some studies have suggested an interplay between
AT1R-Ab and HLA DSA in promoting allograft
injury.16,17
Given AT1R-Ab and HLA DSA activate different
receptors, we hypothesized that their cytokine profiles
may be distinct. Therefore, our aim was to analyze
serum cytokines associated with activation of the AT1R
and vascular inflammation18–23 and distinguish them
from those that associate with HLA DSA. Identifying
cytokine signatures associated with these antibodies541
CLINICAL RESEARCH MH Pearl et al.: AT1R-Ab and Cytokines in Transplantationmay help delineate mechanistic pathways to examine
HLA and non-HLA antibody-mediated injury, lead to
novel clinical monitoring tools, and identify new
therapeutic targets in kidney transplantation.
METHODS
Patients and Study Design
In this retrospective study, 65 pediatric kidney trans-
plant patients were monitored for 2 years posttrans-
plant. From August 2005 to November 2014, 83
patients were enrolled in the University of California
Los Angeles Pediatric Kidney Transplant Immune
Monitoring Study, and 18 patients were excluded from
analysis secondary to missing >1 study sample at the
specified time points. This study was approved by the
University of California Los Angeles Institutional Re-
view Board (#11-002375) and conforms with the 1964
Helsinki declaration and its later amendments or com-
parable ethical standards and the Principles of the
Declaration of Istanbul. Informed consent and, when
appropriate, patient assent was obtained for all pa-
tients. Blood samples were analyzed from early post-
transplant (within the first 3 months), at 6, 12, and 24
months posttransplant, and during suspected episodes
of kidney allograft rejection. In longitudinal analyses,
blood samples were grouped by time point to allow for
analysis of both protocol and clinically indicated samples.
Demographic and clinical data, including age, race,
ethnicity, HLA mismatch, transplant type (deceased/
living donor), time on dialysis, immunosuppression
regimen, and viremia (cytomegalovirus, Epstein-Barr vi-
rus, or BK virus) was collected. Study data were collected
and managed using a secure Research Electronic Data
Capture tool hosted at UCLA.24 Of the 65 patients, 54
patients had complete 2-year follow-up, 7 patients suf-
fered allograft loss, and 4 patients transferred care to a
different institution. No patients died during the study
period. Patient-level outcomes have been previously re-
ported.9 A total of 233 blood samples at the previously
described time points were analyzed. Sample data were
complete with the exception of 1 sample missing HLA
DSA results.
Clinical Protocols and Biopsy Evaluation
Immunosuppressive strategies at our institution included
induction with either antithymocyte globulin for panel
reactive antibodies $30%, delayed graft function, or
rapid-steroid withdrawal protocol or anti-CD25 mono-
clonal antibody for those with panel reactive
antibodies <30%.9 Maintenance immunosuppression
consisted of steroid-free or steroid-based immunosup-
pression, a calcineurin inhibitor, and an antimetabolite.
Acute and chronic rejection were treated with previously
described protocols.25 Cytomegalovirus, Epstein-Barr542virus, and BK virus were monitored monthly for the
first 6 months posttransplant, then at 9, 12, 18, and 24
months posttransplant. Cytomegalovirus and Epstein-
Barr virus viremia were treated with a combination of
i.v. ganciclovir, oral valganciclovir, and reduction in
immunosuppression. BK viremia was treated using pre-
viously described protocols.26
Patients underwent biopsies at 6, 12, and 24 months
posttransplantation per protocol or for clinical indica-
tion. Biopsies were evaluated using 2013 Banff Criteria
by a blinded pathologist.27 Our primary analysis
included all 233 blood samples and evaluated cytokine
profiles, AT1R-Ab, and HLA DSA. To evaluate cyto-
kine profiles in blood samples taken at the time of bi-
opsies with and without biopsy-proven rejection, a
subanalysis of 63 blood samples collected 7 days before
or 3 days after the time of biopsy was conducted. This
window was chosen to account for rapid changes in
serum cytokines both in general and in response to
immunomodulatory therapy. An additional subanalysis
of 129 blood samples collected within 6 weeks of the
time of biopsy was used to evaluate cytokine profiles in
biopsies with and without elevated vascular inflam-
mation scores (arteritis or glomerulitis). A wider win-
dow was chosen for this analysis given that vascular
inflammation scores may be less likely to change
rapidly.28
AT1R and HLA Antibodies and Cytokine Testing
HLA typing of recipient and donor was performed
using molecular methods as previously described.25
HLA antibodies were detected using a Luminex sin-
gle antigen bead assay (Immucor, Stanford, CT) and
quantified by mean fluorescence intensity (MFI). An-
tibodies were considered positive when MFI was $1000
for HLA-A, -B, -DR, -DQ, and $2000 for HLA-C and
-DP.29 AT1R-Ab was measured by enzyme-linked
immunosorbent–based assay (One Lambda, Canoga
Park, CA). Sera were diluted 1:100, tested in duplicate,
and AT1R-Ab concentrations were determined by a
standard curve. AT1R-Ab IgG >17 units/ml was
considered positive.9,30,31 Cytokines were selected based
on a literature review of cytokines that have been asso-
ciated with activation of the AT1R18–23 and measured in
serial posttransplant samples to avoid effects of dialysis
and end-stage renal disease. A custom magnetic bead kit
including TNF-a, IFN-g, IL-8, IL-1b, IL-6, and IL-17
(EMD Millipore, Darmstadt, Germany) was used per
manufacturer’s instructions. Fluorescence was quantified
using a Luminex (Austin, TX) 200TM instrument.
Statistical Methods
Before statistical analysis, cytokines were transformed
using the log(xþ1) transformation due to skew in theirKidney International Reports (2019) 4, 541–550
Table 1. Demographic and clinical characteristics
Variable
n (%)/mean
(SD)/median (IQR)
Age, median (IQR) 15.7 (12.9–17.7)
Sex, male, n (%) 39 (60)
Race, n (%)
White 47 (72.3)
Asian 4 (6.2)
Black 4 (6.2)
Other 10 (15.4)
Etiology of ESRD, n (%)
Obstructive uropathy 16 (24.6)
Dysplasia 9 (13.8)
FSGS 9 (13.8)
Glomerulonephritis 9 (13.8)
PKD 2 (5.3)
Other or unknown 20 (30.8)
Hispanic ethnicity, n (%) 36 (55.4)
Deceased donor, n (%) 40 (61.5)
Mean HLA mismatch 1.2 (0.5)
Time on dialysis, years, median (IQR) 2.2 (1–2.9)
Preemptive transplant, n (%) 14 (21.5)
ATG induction (vs. IL-2 inhibitor), n (%) 6 (9.2)
Steroids-based immunosuppression,
n (%)
31 (47.7)
EBV, CMV, or BK viremia, n (%) 29 (49.2)
Biopsy-proven rejection, n (%) 29 (44.6)
CMV PCR (copies/ml) peak in patients with CMV viremia,
median (IQR)
12,725
(5010–40,936)
EBV PCR (copies/PCR) peak in patients with EBV viremia,
median (IQR)
109 (35–191)
BK PCR (copies/ml) peak in patients with BK viremia,
median (IQR)
9865
(6225–60,375)
Posttransplant HLA DSA positive, n (%) 19 (29.2)
HLA class I positive, n (%) 5 (7.7)
HLA class II positive, n (%) 12 (18.5)
HLA class I and II positive, n (%) 2 (3.1)
HLA DSA–positive samples Class I, MFI, median (IQR) 2258
(1838–3006)
HLA DSA positive samples class II, MFI, median (IQR) 2229 (1902–5500)
MH Pearl et al.: AT1R-Ab and Cytokines in Transplantation CLINICAL RESEARCHdistributions. The value of the lowest lower limit of
detection (LLD) per cytokine was used for values below
the limit of detection. For cytokines in which <50% of
the samples were below the LLD (IL-8, TNF-a, IFN-g),
data were analyzed as a continuous outcome. For cy-
tokines in which >50% of the samples were below the
LLD (IL-1b, IL-6, IL-17) data were analyzed as a cate-
gorical variable (# LLD vs. >LLD). Kruskal-Wallis and
c2 tests were used to compare cytokine levels in blood
samples with and without AT1R-Ab and HLA DSA.
Mixed effects linear and logistic regression models
using a random effect for patients were used to evaluate
the effect of AT1R-Ab and HLA DSA positivity on
cytokines over time. Model results were summarized
using regression coefficients for linear models and odds
ratios for the logistic regression models. Covariates
potentially relevant to elevations in serum cytokines
were included in the models and included age, sex,
mean HLA mismatch, living versus deceased donor,
viremia (presence or absence of cytomegalovirus,
Epstein-Barr virus, or BK virus during the follow-up
period), and rejection (presence or absence of biopsy-
proven rejection, including borderline rejection during
the follow-up period). We also evaluated interaction ef-
fects (time by AT1R-Ab and HLA DSA by AT1R-Ab) in
separate mixed effect linear/logistic regression models.
Time was modeled as a categorical variable to ease
interpretation of regression coefficients. Wilcoxon rank
sum tests were used to compare cytokine levels in sam-
ples associated with biopsies with and without arteritis or
glomerulitis. P values below 0.05 were considered sta-
tistically significant and all tests were 2-sided. The R
Statistical Computing Environment was used for analysis
(R Core Team, Vienna, Austria).AT1R-Ab–positive patients (at any time point , n (%) 38 (58.5)
Preformed AT1R-Ab, n (%) 15 (23.1)
de novo AT1R-Ab, n (%) 17 (26.2)
Positive posttransplant, pretransplant status
unknown, n (%)
6 (9.2)
AT1R-Ab positive samples level (Units/ml), median (IQR) 24 (20–31)
Number of samples per patient, mean (SD) 3.7 (1.1)
Number of samples per time point per patient, mean (SD) 1.2 (0.5)
Number of samples per time point (months
posttransplantation), n (%)
0 (1 d–3 mo) 36 (15.5)
6 (3–9 mo) 70 (30.0)
12 (9–15 mo) 68 (29.2)
24 (16–24 mo) 59 (25.3)
AT1R-Ab, angiotensin II type 1 receptor antibody; ATG, antithymocyte globulin; BKV, BK
virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ESRD, end-stage renal disease;
FSGS, focal segmental glomerulosclerosis; HLA DSA, human leukocyte antigen donor-
specific antibodies; IQR, interquartile range; MFI, mean fluorescence intensity; PCR,
polymerase chain reaction; PKD, polycystic kidney disease.
Blood samples analyzed were from a cohort of 65 pediatric kidney transplant recipients.
These 65 patients yielded 233 blood samples for analysis.RESULTS
Demographics and Immunological Characteristics
of Cohort and Samples
Clinical characteristics of the cohort are briefly
described in Table 1 and comprehensively detailed
elsewhere.9 The rate of rejection during the follow-up
period (including borderline rejection) was 45%. The
rate of viremia with cytomegalovirus, Epstein-Barr vi-
rus, or BK virus was 49%, which is consistent with
other studies that have shown high rates of viremia in
pediatric renal transplant recipients (Table 1).32 AT1R-
Ab >17 units/ml was present in 92 (39%) of 233 blood
samples from 38 (58%) of 65 patients, and HLA DSA
>1000 MFI was present in 25 (11%) of 233 blood
samples from 19 (29%) of 65 patients (Table 1). Most
patients with HLA DSA developed DSA to class II an-
tigens and median MFIs were <3000. The median
AT1R-Ab level in AT1R-Ab–positive patients was 24Kidney International Reports (2019) 4, 541–550units/ml (Table 1). In our previous work, we found that
patients in this cohort who were positive for AT1R-Ab
during the first 2 years posttransplantation had543
CLINICAL RESEARCH MH Pearl et al.: AT1R-Ab and Cytokines in Transplantationsignificantly higher median levels of TNF-a, IL-8, and
IL-1b across time-points during the follow-up period.9
This patient-level data prompted our investigation into
the sample-level data for the current study and to
compare cytokine profiles of HLA DSA.
Cytokines Elevations Differentiate AT1R-Ab
from HLA-DSA
The distribution of cytokine levels in blood samples
positive for AT1R-Ab and HLA DSA are shown in
Figure 1a and b, respectively. AT1R-Ab was a predic-
tor of higher levels of serum inflammatory vascular
cytokines TNF-a, IFN-g, IL-8, IL-1b, IL-6, and IL-17,
which mirrored similar trends in our patient-level
data.9 In comparison, HLA DSA was not associated
with elevations in any of the 6 cytokines. IL-1b, IL-6,
and IL-17 had 61%, 68%, and 76% of values below
the LLD for the assay respectively; therefore, samples
were treated as dichotomous (# LLD ¼ negative vs. >
LLD ¼ positive). In contrast, only 5%, 32%, and 14%
of samples were outside the limits of detection for the
assay for TNF-a, IFN-g, and IL-8, respectively.
Therefore, these cytokines were analyzed as continuous
outcomes.
Given we had more samples positive for AT1R-Ab
than HLA DSA, we conducted a 4-group subanalysis
to preliminarily examine if AT1R-Ab was associated
with increased serum cytokines in samples both with
and without HLA DSA. This also allowed us to assess
the data for any trends suggesting possible synergism.
Overall, the effect of AT1R-Ab on elevations of serum
cytokines remained consistent in samples with and
without HLA DSA (Table 2). Notably, IL-8 and IL-1bFigure 1. Distribution of cytokine data in (a) AT1R-Ab positive (>17 units
negative blood samples. Differences between the groups were evaluated
the outcome variable and AT1R-Ab and HLA DSA as the predictors. All mod
of IL-1b (in all groups except AT1R-Ab positive), IL-6, and IL-17 were equa
angiotensin II type 1 receptor antibody; HLA DSA, human leukocyte antigen
fluorescence intensity; TNF, tumor necrosis factor.
544levels appeared higher in AT1R-Ab–positive and HLA
DSA–negative samples when compared with all other
groups. In contrast, TNF-a and IL-17 were higher in
samples positive for both AT1R-Ab and HLA DSA
when compared with all other groups.
Adjusted Analysis for Clinical Factors Associ-
ated With Increased Cytokine Levels
As serum cytokines can be influenced by multiple
factors, we examined models that controlled for rele-
vant clinical variables, including age, sex, mean HLA
mismatch, living versus deceased donor, time post-
transplant, viremia, and rejection. After controlling for
these factors, the relationship between AT1R-Ab and
all 6 cytokines remained significant (Table 3). Time
posttransplant was associated with cytokine levels for
all cytokines except IL-6. In the multivariable model,
living donor (P ¼ 0.013) and mean HLA mismatch (P ¼
0.04) were also associated with detectable IL-6 levels
(data not shown).
To follow up our preliminary examination of the
data by both AT1R-Ab and HLA DSA status as noted
previously, we assessed the interaction effects between
HLA DSA and AT1R-Ab on cytokine levels. Although
there appeared to be a potential trend in the data to-
ward synergism for TNF-a and IL-17 in the initial
analysis, a regression model showed there were no
statistically significant interaction effects (data not
shown).
Given the potential importance of rejection in
influencing cytokine levels and the possibility of serum
cytokine levels changing fairly rapidly over the course
of days, we conducted a subanalysis of samples that/ml) versus negative and (b) HLA DSA positive (MFI >1000) versus
using linear mixed effects regression models with each cytokine as
els are controlled for patient-level random effect. The median levels
l to the lower limit of detection for the respective cytokine. AT1R-Ab,
donor-specific antibodies; IFN, interferon; IL, interleukin; MFI, mean
Kidney International Reports (2019) 4, 541–550
Table 2. Comparison of cytokine levels in blood samples with and without AT1R-Ab and HLA DSA
Cytokine HLA DSA-- AT1R-Ab-- (n [ 126) HLA DSA-- AT1R-AbD (n [ 81) HLA DSAD AT1R-Ab-- (n [ 14) HLA DSAD AT1R-AbD (n [ 11) P
pg/ml Median (IQR) Median (IQR) Median (IQR) Median (IQR)
TNF-a 8.8 (5.76–14.4) 11.11 (7.83–16.56) 7.8 (5.15–8.48) 20.44 (5.33–43.05) 0.023
IFN-g 3.57 (0.29–11.37) 8.52 (4.07–19.84) 5.88 (0.92–17.5) 4.13 (0.58–13.35) 0.006
IL-8 6.11 (2.06–16.72) 19.94 (7.67–46.56) 7.03 (0.18–41.75) 10.22 (4.46–65.69) <0.001
% >LLD n (%) n (%) n (%) n (%)
IL-1b 34 (26.98) 44 (54.32) 5 (35.71) 3 (27.27) 0.001
IL-6 32 (25.4) 34 (41.98) 4 (28.57) 5 (45.45) 0.069
IL-17 26 (20.63) 21 (25.93) 2 (14.29) 5 (45.45) 0.249
AT1R-Ab, angiotensin II type 1 receptor antibody; HLA DSA, human leukocyte antigen donor-specific antibodies; IFN, interferon; IL, interleukin; IQR, interquartile range; TNF, tumor
necrosis factor.
For cytokines with <50% of samples above the lower limit of detection (LLD) (TNF-a, IFN-g, IL-8) data are summarized as median and IQR and compared using the Kruskal-Wallis test.
For cytokines in which $50% of samples were below the LLD (IL-1b, IL-6, IL-17) data are summarized as percent positive where positive is >LLD and compared using c2 test. The
comparison of all 4 groups was statistically significant for all cytokines except IL-6 and IL-17.
MH Pearl et al.: AT1R-Ab and Cytokines in Transplantation CLINICAL RESEARCHwere collected within 7 days before and 3 days after a
biopsy (see Methods). Of the 233 samples, 63 met
this criterion. An analysis of these samples revealed
a potential association between IL-8 and acute biopsy-
proven rejection; however, these results were
inconclusive secondary to poor model fit. On this
subanalysis, there was also no association between any
of these cytokines and the presence of any acute or
chronic vascular findings. However, on analysis of all
biopsy-matched samples ( 6 weeks) in the cohort, we
found blood samples with arteritis and glomerulitis had
significantly higher levels of IL-8, IL-1 b, and IL-6 (P ¼
0.010, P ¼ 0.038, P ¼ 0.010), consistent with our
patient-level data in patients who were AT1R-Ab
positive (Table 4).9
The Relationship Between Time Posttransplant
and Cytokine Levels
Time posttransplant was significantly associated with
cytokine levels for all cytokines except for IL-6Table 3. Multivariable models for effect of AT1R-Ab or HLA DSA
positivity on cytokine levels
Cytokine AT1R-AbD (n [ 92) P HLA DSAD (n [ 25) P
Linear modelsa Coefficient (95% CI) Coefficient (95% CI)
TNF-a 0.38 (0.14–0.63) 0.002 0.01 (0.42 to 0.39) 0.883
IFN-g 0.71 (0.25–1.18) 0.002 0.35 (0.38 to 1.08) 0.360
IL-8 1.04 (0.61–1.47) <0.001 0.45 (0.24 to 1.14) 0.221
Logistic
modelsb
OR (95% CI) OR (95% CI)
IL-1b 3.03 (1.32–6.96) 0.008 0.86 (0.25–2.96) 0.817
IL-6 3.89 (1.34–11.36) 0.012 2.74 (0.55–13.58) 0.155
IL-17 2.56 (0.99–6.62) 0.049 1.26 (0.32–4.89) 0.714
AT1R-Ab, angiotensin II type 1 receptor antibody; CI, confidence interval; HLA DSA,
human leukocyte antigen donor-specific antibodies; IFN, interferon; IL, interleukin; LLD,
lower limit of detection; OR, odds ratio; TNF, tumor necrosis factor.
Individual linear and logistic regression models were created for each cytokine. Linear
models were used when <50% of samples were below the LLD (TNF-a, IFN-g, IL-8) and
logistic models were used otherwise (IL-1b, IL-6, IL-17). Viremia and rejection were
assessed on the patient level as any viremia or rejection during the follow-up period.
Time posttransplantation was significant for all cytokines except IL-6.
aLinear regression models adjusted for patient level random effect, time, age, sex, mean
HLA mismatch, living versus deceased donor, viremia, and presence of rejection.
Cytokines log transformed for analysis.
bLogistic regression models adjusted for patient-level random effect, time, age, sex,
mean HLA mismatch, living versus deceased donor, and presence of rejection.
Kidney International Reports (2019) 4, 541–550(Figure 2a–f). Given the significant individual associa-
tions of time and AT1R-Ab on cytokine levels, we
assessed for any interaction effect between these 2
variables. We found no significant interaction sug-
gesting that the impact of AT1R-Ab on cytokine levels
was consistent across all time points posttransplant
(data not shown).
DISCUSSION
Wedemonstrate that AT1R-Ab has significant associations
with vascular inflammatory cytokines TNF-a, IFN-g, IL-8,
IL-1b, IL-6, and IL-17 and renal vascular biopsy findings
distinct from HLA DSA in pediatric renal transplantation.
The association between AT1R-Ab and these serum cyto-
kines remained significant even when controlling for HLA
DSA, in addition to time posttransplant, age, sex, mean
HLA mismatch, donor type, presence of rejection, and
viremia. Moreover, our longitudinal samples allowed us to
demonstrate the consistency of the relationship between
AT1R-Ab and cytokine elevations over time. This unique
cytokine profile suggests that AT1R-Ab may activate
different pathways from HLA DSA and potentially exert
renal allograft damage through a separate mechanism.
Since the original paper describing AT1R-Ab in
patients with acute AMR and hypertension,8 multiple
studies9,16,17,33–40 have indicated an associationTable 4. Comparison of cytokines in blood samples associated with
biopsies with and without arteritis or glomerulitis
Cytokine gDv [ 0 (n [ 125) gDv > 0 (n [ 4) P
pg/ml Median (IQR) Median (IQR)
TNF-a 9.2 (6.6–14.5) 9.1 (7.5–107.9) 0.704
IFN-g 7.2 (0.6–25.2) 10.1 (7–1689.7) 0.608
IL-8 7.8 (3.5–31.1) 61.9 (44.3–770.8) 0.010
IL-1b 0.2 (0.2–2.1) 8.3 (5.6–68.8) 0.038
IL-6 0.3 (0.3–4.7) 6.1 (4.9–95.1) 0.010
IL-17 0.3 (0.3–2.7) 1.1 (0.3–225.5) 0.323
IFN, interferon; IL, interleukin; IQR, interquartile range; TNF, tumor necrosis factor.
Cytokine levels in blood samples collected within 6 weeks of biopsies with and without
glomerulitis (g) or arteritis (v) were compared using the Wilcoxon rank sum test. IL-8, IL-
1b, and IL-6 were elevated in samples associated with biopsies with arteritis or
glomerulitis.
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Figure 2. Cytokine levels by AT1R-Ab status over time. Relationship of (a) TNF-a, (b) IFN-g, (c) IL-8, (d) IL-1b, (e) IL-6, and (f) IL-17 and AT1R-Ab
status in blood samples by time posttransplantation. Time posttransplant (except in the case of IL-6) was significantly associated with elevation
in serum cytokine levels. The interaction between time and AT1R-Ab evaluated in separate models was not significant. This may indicate that
the effect of AT1R-Ab status on each cytokine was constant over time. AT1R-Ab, angiotensin II type 1 receptor antibody; IFN, interferon; IL,
interleukin; LLD, lower limit of detection; TNF, tumor necrosis factor.
CLINICAL RESEARCH MH Pearl et al.: AT1R-Ab and Cytokines in Transplantation
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MH Pearl et al.: AT1R-Ab and Cytokines in Transplantation CLINICAL RESEARCHbetween AT1R-Abwith vascular inflammation and poor
clinical outcomes. Studies with longitudinal measure-
ments of AT1R-Ab9,16,36 remain limited. Furthermore,
although AT1R-Ab has been reported to potentially
synergize with HLA DSA,16,40 their mechanistic inter-
action remains unclear. Our initial work revealed an
association between AT1R-Ab and IL-8, IL-1b, and
TNF-a in patients with AT1R-Ab at any time during the
first 2 years posttransplant.9 As cytokines may fluctuate
rapidly, we undertook this additional analysis to
examine the relationship between AT1R-Ab, HLA DSA,
and cytokines at the sample level with the aim of
elucidating differences in inflammatory profiles.
Because AT1R-Ab has been shown to be an allosteric
agonist7,8 of the AT1R, we measured cytokines associ-
ated with activation of the AT1R and vascular inflam-
mation. Angiotensin II has been shown to stimulate
TNF-a production in glomerular endothelial cells in
rats,41 and both IL-17 and IFN-g are involved in
angiotensin II–mediated increases in blood pressure
and salt retention in mice.19 Angiotensin II–treated
renal proximal tubular cells and mouse macrophages
secrete IL-1b, IL-6, IL-8, and TNF-a.20,42 In addition,
IL-8 and IL-6 have been implicated in the pathophys-
iology of other vascular inflammatory conditions asso-
ciated with AT1R-Ab, such as preeclampsia and
scleroderma.18,21,22,43 Based on these in vitro and animal
model data, we examined these specific cytokines in
patients expected to have elevated AT1R signaling.
Accordingly, we found that AT1R-Ab was associated
with significant elevations of these cytokines in renal
transplant recipients in vivo. In the multivariable models,
the relationship between cytokines and AT1R-Ab
remained consistent when controlling for other clinical
variables, and only IL-6 had other significant predictors
(aside from time). The additional association of IL-6 with
living donationmay be reflective of regenerative processes
occurring in the allograft,44 but this relationship requires
further investigation. In addition, the cytokines had
varying levels during the early posttransplant time point,
which may be partially reflective of a proinflammatory
state associated with end-stage renal disease. Although the
potential immune effects of AT1R signaling are com-
plex,45–47 activation of AT1R is considered to be proin-
flammatory, which is consistent with our data.
The 6 cytokines measured in our study are involved
in vascular inflammatory pathways23 and may provide
insights into AT1R-Ab pathogenesis. Endothelial cells
can produce IL-1b and IL-8, which are known to pro-
mote leukocyte chemotaxis and artherogenesis.23,48–50
Elevations in IL-651–56 and TNF-a54,57,58 also have
been associated with rejection, mortality, and allograft
loss in renal transplantation. Interestingly, in our
analysis, the association between AT1R-Ab and theseKidney International Reports (2019) 4, 541–550cytokines remained significant even when controlling
for rejection. Taken together, these data suggest AT1R-
Ab may cause vascular inflammation that is not
necessarily exclusively associated with acute rejection.
This is consistent with our patient-level clinical find-
ings in this cohort of (i) decline in estimated glomerular
filtration rate in patients with AT1R-Ab both with and
without rejection, and (ii) the association between AT1R-
Ab and arteritis or glomerulitis on biopsy.9 Furthermore,
arteritis or glomerulitis on biopsy was associated with
elevations in IL-8, IL-1b, and IL-6 at the sample level.
Therefore, our data may provide guidance in investi-
gating novel therapeutic targets. The IL-6 inhibitor
tocilizumab has been used in a small number of cases to
treat AT1R-Ab–associated AMR.28 TNF-a inhibition
is currently being trialed in the prevention of ischemia
reperfusion injury (ClinicalTrials.gov Identifier:
NCT02495077) in renal transplantation. Furthermore,
there is the potential to use IL-1 and IL-17 blockers,
currently approved for the treatment of autoimmune
conditions, in the context of transplantation.59,60 Addi-
tional study is required to understand the roles of these
pathways and potential for pharmacologic intervention.
By contrast, there were no statistically significant
associations between HLA DSA and increases in serum
cytokines in our cohort. Although we chose cytokines
based on described AT1R pathways, this was still
somewhat unexpected, given elevations in cytokines in
our panel also have been associated with HLA Class I
and II signaling in vitro. Activation of endothelial cells
by HLA Class I has been associated with increases in
IL-1b, IL-6, IL-8, and TNF-a.61,62 HLA class II binding
has been associated with increased IL-6 production in
endothelial cells and promotion of TH17 lymphocyte
expansion.63 In peripheral blood mononuclear cells
isolated from transplant patients, some studies have
shown HLA antibodies increase cytokines (TNF-a, IFN-
g, and IL-664) whereas others have not.65 We found an
association between IL-6 and HLA mismatch, but not
HLA DSA. Several factors may have affected the anal-
ysis of these relationships in our cohort. HLA DSAs
were less prevalent in our samples than AT1R-Ab,
which may have reduced our power to detect differ-
ences. We mitigated this by using a model that
simultaneously included both HLA DSA and AT1R-Ab.
Furthermore, most of the HLA DSAs in our cohort were
low to moderate MFI and our samples were drawn
relatively early posttransplantation. It is possible that
we may have observed an effect of HLA DSAs on these
cytokines, particularly IL-6, in samples with higher
MFIs or from time points later posttransplantation.
We used statistical approaches in our model to limit
the impact of the different event rates for AT1R-Ab and
HLA DSA positivity on our ability to detect factors with547
CLINICAL RESEARCH MH Pearl et al.: AT1R-Ab and Cytokines in Transplantationgreater associations with elevations in serum cytokines.
The low event rate for HLA DSA–positive samples
limited our ability to do subanalyses by HLA Class or
MFI. In addition, we examined cytokines previously
associated with AT1R activation, which would not have
accounted for all cytokines that could be associated with
HLA DSA. We also acknowledge other potential study
limitations. Most blood samples did not have time-
matched biopsy samples per our previously described
criteria. This limited our ability to effectively analyze
direct temporal relationships between cytokine profiles
and biopsy findings. Cytokine levels fluctuate quickly
and may be rapidly affected by treatment for rejection.
Therefore, we limited our primary analyses to relating
antibodies with cytokines because they were all tested in
the same blood samples. The availability of longitudinal
samples, however, allowed us to assess relationships at
multiple time points posttransplantation. We also were
able to take advantage of the rich clinical data available
on our cohort to control for potential confounders.
In conclusion, we describe a unique inflammatory
cytokine profile for AT1R-Ab in patients with renal
transplantation. Currently, the differences in non-HLA
and HLA antibody-mediated allograft injury are poorly
understood. This profile of vascular cytokines may
inform the design of future studies to elucidate the
distinct pathophysiology of AT1R-Ab–mediated injury
in kidney transplantation, develop adjunct clinical
monitoring tools, and help identify potential thera-
peutics, specifically targeting cytokines, for the treat-
ment of non-HLA antibody-mediated allograft injury.DISCLOSURE
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